Zhiwei Wu

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu, Yaling Hu, Miao Xu et al. · The Lancet Infectious Diseases · 2021 · 572 citations · Full text

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Bihua Han, Yufei Song, Changgui Li et al. · The Lancet Infectious Diseases · 2021 · 351 citations · Full text

Vaccination, Vaccine Safety, Vaccinology +8

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Gang Zeng, Qianhui Wu, Hongxing Pan et al. · The Lancet Infectious Diseases · 2021 · 284 citations · Full text

Vaccination, Vaccine Safety, Coronary Unit +8

Visualising the expansion and spread of coronavirus disease 2019 by cartograms

Peichao Gao, Hong Zhang, Zhiwei Wu et al. · Environment and Planning A Economy and Space · 2020 · 50 citations · Full text

Virus Epidemiology, Viral Diagnostics, Geovisualization +24

A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Minjie Li, Juan Yang, Lin Wang et al. · 2021 · 37 citations · Full text

Immunology, Immunodominance, Vaccine Hesitancy +23